Amunix announces licensing agreement with Merck for ProTIA platform

Amunix Pharmaceuticals announced that it has entered into a licensing agreement with Merck for rights to develop therapeutics against an undisclosed target using Amunix’s proprietary protease-triggered immune activator, or ProTIA, technology platform. Under terms of the agreement, Amunix will receive an upfront payment from Merck and is eligible to receive payments associated with the achievement of certain developmental milestones as well as royalties on sales of any products derived from the collaboration. Further financial details were not disclosed.
https://thefly.com/landingPageNews.php?id=2843439